1. Introduction Atrial fibrillation (AF) is a growing clinical concern with a rising prevalence, often co-occurring with cancer due to shared risk factors, with up to one in four patients having both [1]. Moreover, cancer therapies with cardiovascular toxicity may increase the risk of AF [2]. This intersection of arrhythmia and malignancy presents a complex and significantly escalating challenge in managing thromboembolic and hemorrhagic risks [3], posing a dual threat to patients’ overall health.
Gilad Margolis
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Gilad
Contact Gilad, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack